Efficacy and Safety of Rovalpituzumab Tesirine Compared With Topotecan as Second-Line Therapy in DLL3-High SCLC: Results From the Phase 3 TAHOE Study

DLL3, an atypical Notch ligand, is expressed in SCLC tumors but is not detectable in normal adult tissues. Rovalpituzumab tesirine (Rova-T) is an antibody-drug conjugate containing a DLL3-targeting antibody tethered to a cytotoxic agent pyrrolobenzodiazepine by means of a protease-cleavable linker....

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of thoracic oncology 2021-09, Vol.16 (9), p.1547-1558
Hauptverfasser:	Blackhall, Fiona, Jao, Kevin, Greillier, Laurent, Cho, Byoung Chul, Penkov, Konstantin, Reguart, Noemi, Majem, Margarita, Nackaerts, Kristiaan, Syrigos, Konstantinos, Hansen, Karin, Schuette, Wolfgang, Cetnar, Jeremy, Cappuzzo, Federico, Okamoto, Isamu, Erman, Mustafa, Langer, Seppo W., Kato, Terufumi, Groen, Harry, Sun, Zhaowen, Luo, Yan, Tanwani, Poonam, Caffrey, Laura, Komarnitsky, Philip, Reinmuth, Niels
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Antibodies, Monoclonal, Humanized Antineoplastic Combined Chemotherapy Protocols - therapeutic use Benzodiazepinones Cancer Delta-like protein 3 Human health and pathology Humans Immunoconjugates - therapeutic use Intracellular Signaling Peptides and Proteins Life Sciences Lung Neoplasms - drug therapy Membrane Proteins Middle Aged Pulmonology and respiratory tract Rovalpituzumab tesirine Small cell lung cancer Small Cell Lung Carcinoma - drug therapy Topotecan Topotecan - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!